A notable increase in the incidence of incurable prostate cancer cases is prompting a reevaluation of Canada’s approach to screening for one of the most prevalent diseases affecting men, as revealed by recent research findings.
The latest study, featured in Current Oncology, analyzed decades of data on prostate cancer cases and fatalities. It highlighted a rise in advanced-stage cancers alongside a stabilization in mortality rates, which had been steadily declining. Dr. Anna Wilkinson, the study’s lead author and a family physician affiliated with the University of Ottawa, emphasized that while it was challenging to determine who underwent screening, the substantial number of cases provided insights into the implications of screening practices.
However, some oncologists challenge the interpretation of the data, arguing that the prostate-specific antigen (PSA) test, a screening tool, is unreliable and may lead to unnecessary treatments and overdiagnosis. They caution against the potential harms associated with the test.
The study pointed out shifts in screening approaches, noting that while the Canadian prevention task force historically refrained from endorsing prostate cancer screening, the introduction of the PSA test in the U.S. in the early 1990s influenced a significant adoption in Canada. Subsequently, both countries moved away from widespread screening in the early 2010s, allowing researchers to observe changes in case and mortality rates against evolving recommendations.
The study indicated a surge in late-stage prostate cancer following the shift away from screening, prompting discussions among experts. Some experts view the decline in mortality rates as a result of advancements in prostate cancer treatment rather than screening practices.
The debate centers on the controversial PSA test, which measures a prostate-specific protein and is deemed inaccurate by some experts due to potential false positives. Concerns revolve around the downstream implications of positive test results, including the need for invasive diagnostic procedures like biopsies and the risks associated with unnecessary treatments.
As discussions on prostate cancer screening continue, new guidance on cancer screening, including prostate cancer, is anticipated next year following a review that temporarily halted the Canadian Task Force on Preventive Health Care’s activities. The Canadian Cancer Society and Canadian Urological Association recommend PSA screening after thorough discussions on the risks and benefits with healthcare providers.